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Abstract: We aimed to investigate associations of the dietary inflammatory index (DII) with
glucose-insulin homeostasis markers, and the risk of glucose intolerance. This cross-sectional study
included 2975 adults from the Tehran Lipid and Glucose Study. Fasting plasma glucose (FPG), 2-h
post-load glucose (2h-PG), and fasting serum insulin were measured. Homeostatic model assessment
of insulin resistance index (HOMA-IR) and β-cell function (HOMA-B), and the quantitative insulin
sensitivity check index (QUICKI) were calculated. Glucose tolerance abnormalities included impaired
fasting glucose (IFG), impaired glucose tolerance (IGT), and type 2 diabetes (T2DM). DII scores
were positively associated with 2h-PG (β = 0.04; p = 0.05). There was no significant linear trend
across quartiles of DII for adjusted means of glucose-insulin homeostasis markers. Participants in the
highest quartile of DII score tended to have higher FPG compared to those in the second quartile
of DII score (5.46 vs. 5.38 mmol/L, p = 0.07) and higher fasting insulin and HOMA-IR compared
to those in the lowest quartile (8.52 vs. 8.12 µU/mL for fasting insulin, p = 0.07; 2.06 vs. 1.96 for
HOMA-IR, p = 0.08). No significant associations were observed between DII and risk of IFG, IGT,
T2DM, and insulin resistance. Among glucose-insulin homeostasis markers, DII had a positive weak
association only with 2h-PG.
Keywords: dietary inflammatory index; glucose metabolism; insulin sensitivity; glucose
tolerance abnormality
1. Introduction
Type 2 Diabetes Mellitus (T2DM) is emerging as one of the most important epidemics of the
21st century, with devastating health and economic impacts [1]. It has been reported that 382 million
people in the world had T2DM in 2013, a number expected to increase in the future, reaching 592 million
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in 2035 [2]. Globally, 1.5 million adult deaths and 89 million disability-adjusted life-years (DALY) in
2012 have been attributed to diabetes [3].
With the emergence of industrial agriculture and widespread food processing, there
have been massive changes in the dietary behaviors and nutritional status of the world’s
population. These changes constitute a significant contribution to the generation of T2DM and
other inflammation-related diseases [4]. Observational studies from Iran indicate significant
associations between dietary factors and markers of glucose metabolism, and risk of T2DM [5–8].
However, associations between quality aspects of diet, markers of glucose and insulin metabolism, and
risk of glucose tolerance abnormalities such as impaired fasting glucose (IFG) and impaired glucose
tolerance (IGT), and insulin resistance (IR) remain to be investigated.
Dietary components can exert pro-inflammatory or anti-inflammatory effects, which may
influence the risk of inflammatory diseases [9,10]. The dietary inflammatory index (DII) is a newly
developed tool for assessing the inflammatory properties of the diet based on intake of macronutrients,
micronutrients and some other dietary constituents [11]. The DII score is calculated using inflammatory
scores of each food parameters and their standardized intakes relative to global values. Previous studies
have shown that DII is associated with increased inflammatory biomarkers [12,13], incidence of
cardiovascular disease [14] and some cancers [15–17], lung function and asthma [18], adiposity
measures [19], and bone mineral density in postmenopausal women [20]. Studies on the associations
between DII and markers of glucose metabolism including fasting plasma glucose (FPG), 2-h post-load
glucose (2h-PG), and insulin report inconsistent findings [21–23], and the associations between DII
and the risk of glucose tolerance abnormalities including IFG, IGT, and T2DM have not been reported
previously. Therefore, the present study aims to examine the associations of the DII with markers of
glucose-insulin homeostasis, and with the risk of glucose tolerance abnormalities and insulin resistance
in an Iranian population.
2. Methods
2.1. Participants
This cross-sectional study is based on data from the Tehran Lipid and Glucose Study (TLGS),
an ongoing community-based cohort study aiming to investigate the prevalence and incidence of
chronic diseases and their risk factors [24]. The TLGS was initiated in 1999–2001 with 15,005 subjects,
aged ≥ 3 years, who were residents of district 13 of Tehran. After determining the prevalence of chronic
diseases and their risk factors at baseline examination, participants have been followed every three
years to update their information. In this study, the data collected at the fourth follow-up examination
(2009–2011) was used. Of 12,523 individuals, who participated in the fourth follow-up examination,
7931 individuals were randomly selected for dietary assessments. For the current study, 6722 men
and women, aged 19–75 years were selected. Pregnant and lactating women and those with missing
information on fasting blood glucose, those with a history of stroke, cancer, myocardial infarction
and non-ischemic disease were excluded. Participants with total energy intake outside predefined
limits (n = 645; total energy intake <800 kcal/day or >4200 kcal/day for men; <600 kcal/day or
>3500 kcal/day for women) and individuals with outlier intakes of at least one of the food parameters
(n = 323; ≥3.3 standard deviation (SD)) also were excluded. Finally, 5451 participants remained,
of whom 2975 subjects were randomly selected for insulin measurements and further investigations in
this study (Figure 1). The ethics committee of the Research Institute for Endocrine Sciences of Shahid
Beheshti University of Medical Sciences approved the study protocol, and written informed consent
was obtained from all participants.






Information  on  demographic,  past medical  history,  current medications  use  and  smoking 
habits  of  participants were  obtained  using  a  pretested  questionnaire  administered  by  trained 
interviewers [24]. Subjects who smoked daily or occasionally were considered as current smokers; 
whereas non‐smokers  included  those who had never  smoked or  those who had quit  smoking. 
Weight and height were measured, and body mass  index  (BMI) was calculated. Blood pressure 
(BP) was measured by a standardized mercury sphygmomanometer, twice on the right arm in a 
seated  position,  after  a  rest  period  of  15  min;  the  average  of  the  two  measurements  was 
considered  as  participant’s  BP. Hypertension was  defined  as  systolic  blood  pressure/diastolic 
blood pressure ≥130/85 or taking anti‐hypertensive drugs. Physical activity  levels were assessed 
using  the Persian  translated Modifiable Activity Questionnaire (MAQ)  [25], which measured all 
three  types of activity  including  leisure  time,  job and household activities  in  the past year and 
expressed  as metabolic  equivalent  (MET) minutes per week. Physical  activity was  categorized 
into four groups (missing, and MET score in tertiles). Tertiles of physical activity were defined as 
≤94.1, >94.1 to ≤498.5, and >498.5 MET‐min/week. 
Blood  samples  were  taken  from  all  participants  at  the  TLGS  research  laboratory  after  an 
overnight  fast of 12–14 h. FPG and 2‐hPG were assayed by enzymatic colorimetric method using 
glucose  oxidase  (Pars  Azmoon,  Tehran,  Iran)  and  a  Selectra  2  Autoanalyzer  (Vital  scientific, 
Spankeren, The Netherlands) with both  intra‐ and  inter‐assay  coefficients of variation  (CVs)  less 




Diabetes Mellitus was  defined  according  to  the  American  Diabetes Association  (ADA),  as 
fasting glucose ≥7.0 mmol/L or 2‐hPG ≥11.1 mmol/L and/or use of anti‐diabetic medication; IFG was 
defined  as  fasting glucose  5.6–6.9 mmol/L  and  IGT was defined  as  2‐hPG  7.8–11.0 mmol/L  [26]. 
Insulin  resistance/sensitivity were  calculated  as  follows: Homeostatic model  assessment  insulin 
resistance  index  (HOMA‐IR)  =  [fasting  insulin  (μU/mL)  ×  fasting  glucose  (mmol/L)]/22.5; 
Homeostatic model of β‐cell  function  (HOMA‐B) =  [20 ×  fasting  insulin  (μU/mL)]/fasting glucose 
(mmol/L)  − 3.5;  the quantitative  insulin  sensitivity  check  index  (QUICKI)  = 1/[log  fasting  insulin 
(μU/mL) + log fasting glucose (mg/dL)]. IR was defined as HOMA‐IR ≥1.86 in women, and ≥1.34 in 
men [27]. 
Figure 1. Selection of study participants.
2.2. Clinical and Biochemical Measurements
Information on demographic, past medical history, current medications use and smoking habits of
participants were obtained using a pretested questionnaire administered by trained interviewers [24].
Subjects who smoked daily or occasionally were considered as current smokers; whereas non-smokers
included those who had nev r smoked or those who had quit smoking. Weight and height were
measured, and body mass index (BMI) was calculated. Blood pr ssure (BP) was measured by a
standar ized mercury sphygmomanometer, tw ce on the i ht arm in a seat d position, after a
rest period of 15 min; the average of th tw measurem nts was considered as pa ticipant’s BP.
Hypertension was defined as systolic blood pressure/diastolic blood pressure ≥130/85 or taking
anti-hypertensive drugs. Physical activity levels were assessed using the Persian translated Modifiable
Activity Questionnaire (MAQ) [25], which measured all three types of activity including leisure time,
job and household activities in the past year and expressed as metabolic equivalent (MET) minutes
per week. Physical activity was categorized into four groups (missing, and MET score in tertiles).
Tertiles of physical activity were defined as ≤94.1, >94.1 to ≤498.5, and >498.5 MET-min/week.
Blood samples were taken from all participants at the TLGS research laboratory after an overnight
fast of 12–14 h. FPG and 2-hPG were assayed by enzymatic colorimetric method using glucose
oxidase (Pars Azmoon, Tehran, Iran) and a Selectra 2 Autoanalyzer (Vital scientific, Spankeren,
The Netherlands) with both intra- and inter-assay coefficients of variation (CVs) less than 2%.
Fasting serum insulin was determined by the electrochemiluminescence immunoassay (ECLIA)
method, using Roche Diagnostics kits and the Roche/Hitachi Cobas e-411 analyzer (GmbH, Mannheim,
Germany). Intra- and inter-assay CVs were 1.2% and 3.5%, respectively.
2.3. Outcome Definitions
D abetes M llitus was defined according to the American Diabe es Association (ADA), as fasting
glucose ≥7.0 mmol/L or 2-hPG ≥11.1 mmol/L and/or use of anti-diabetic medication; IFG was
defi ed as fasting glucose 5.6–6.9 mmol/L and IGT as defined s 2-hPG 7.8–11.0 mmol/L [26].
Insulin resista ce/sensitivity were calculated as follows: Homeostatic model assessment insulin
resistance index (HOMA-IR) = [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5;
Homeostatic model of β-cell function (HOMA-B) = [20 × fasting insulin (µU/mL)]/fasting glucose
(mmol/L) − 3.5; the quantitative insulin sensitivity check index (QUICKI) = 1/[log fasting insulin
(µU/mL) + log fasting glucose (mg/dL)]. IR was defined as HOMA-IR ≥1.86 in women, and ≥1.34 in
men [27].
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2.4. Dietary Assessment and Calculation of the Dietary Inflammatory Index
Information about the usual diets of the participants during the preceding year was gathered
using a validated and reliable semi-quantitative food frequency questionnaire (FFQ) [28,29], which
consisted of 168 dietary items with standard portion sizes and participants were asked to designate
their frequency of consumption for each food item, on a daily, weekly, monthly or yearly basis.
These reported intakes were first converted to daily frequencies, and then were converted to grams.
Energy and nutrient contents of food items were analyzed using the USDA Food Composition Table
(FCT) and for traditional Iranian food that were not provided by the USDA FCT, the Iranian food
composition table was used. Flavonoid contents of foods were calculated based on linkage with the
USDA database for flavonoid content of selected foods.
Data on intakes of 37 food parameters including carbohydrate, protein, total fat, cholesterol,
saturated fatty acids, trans fatty acids, monounsaturated fatty acids (MUFA), polyunsaturated fatty
acids (PUFA), n-3 fatty acids, n-6 fatty acids, fiber, folic acid, niacin, riboflavin, thiamin, vitamin A,
vitamin C, vitamin D, vitamin E, vitamin B6, vitamin B12, iron, zinc, selenium, magnesium, β-carotene,
flavan-3-ol, flavones, flavonols, flavonones, anthocyanidins, isoflavones, onion, garlic, pepper, caffeine
and tea were used to calculate the DII. All food parameters were adjusted for energy using the energy
density method [30], therefore, energy-adjusted intakes of food parameters were used to construct of
the DII. The DII construction procedure has been reported elsewhere [11]. Briefly, adjusted intake of
food parameters for each individual is standardized to its corresponding global mean and standard
deviation. The derived Z score values were converted to percentile and centered, by doubling the
values and subtracting one, to normalize the scoring system and to avoid skewness. The centered
percentile value for each food parameter is then multiplied by its respective overall food parameter
score to obtain the food parameter-specific DII score. Finally, the DII score was determined by summing
all of the food parameter-specific DII score. The greater the DII score, the more pro-inflammatory the
diet and more negative scores demonstrate a more anti-inflammatory diet. Validity of the DII score
was reported based on a 24-h dietary recall and a structured questionnaire similar to FFQ [13].
2.5. Statistical Analysis
Characteristics of participants across quartiles of the DII were compared using one-way analysis
of variance (ANOVA) with Tukey’s post hoc test for continuous variables (presented as means ± SD)
and chi-square tests for categorical variables (presented as percentage). All of the glucose metabolism
markers were skewed; therefore, the natural logarithmic transformed (Ln) values were used in
analyses. The associations between DII, as a continuous variable, and markers of glucose metabolism
were assessed using linear regression analyses. Furthermore, adjusted geometric means of glucose
metabolism markers across quartile of the DII score were determined using analysis of covariance
(ANCOVA). To assess odds of glucose tolerance abnormalities and IR according to quartiles of DII
score, the adjusted odds ratios (ORs) with 95% CIs were estimated using logistic regression analyses,
considering the lowest quartile as the reference group. In all analyses, sex, age (continuous), smoking
status (smoker/nonsmoker), physical activity (MET score in tertiles, or missing), a family history of
diabetes (yes/no, or missing), hypertension (yes/no), glucose lowering medications (yes/no) and
lipid lowering medications (yes/no) were included in model 1 as covariates. BMI (<18.5 kg/m2,
18.5–24.99 kg/m2, 25–29.99 kg/m2 and ≥30 kg/m2, or missing) was included in model 2 in addition
to the covariates of model 1. In the models of assessing the risk of glucose tolerance abnormality and
T2DM, we did not include glucose lowering medication since it was considered as criteria for diagnosis
of T2DM. P for trend across quartiles was computed by assigning each participant the median score
for the quartiles and modeling this value as a continuous variable. The Statistical Packages for Social
Sciences (SPSS version 20; Chicago, IL, USA) were used to perform analyses and p-values ≤ 0.05 were
considered significant.
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3. Results
The mean (±SD) age of the study participants was 45 ± 11.7 years, and 56% of participants were
women. The DII ranged from −5.82 to 5.23 with the median of −3.43 in the lowest quartile and 1.24 in
the highest quartile. Diabetes risk factors and other characteristics of the participants according to
the DII score quartiles are presented in Table 1. Participants in the highest quartile of DII score were
significantly younger, more likely to be men, had the lowest BMI, and the lowest percentage of having
hypertension and of using glucose- and lipid-lowering medications. Moreover, participants with a
higher DII score were less physically active and had a higher proportion of smokers than those in the
lowest quartile.
Table 1. Characteristics of participants according to the quartiles of the dietary inflammatory
index (DII).
Characteristics
Quartiles of the DII
Q1 (n = 743) Q2 (n = 744) Q3 (n = 744) Q4 (n = 744) p *
DII
Median −3.43 −1.96 −0.48 1.24
Minimum, maximum −5.82,<−2.67
−2.67,
<−1.23 −1.23, <0.29 0.29, 5.23
Age, years 47.8 ± 11.6 45.8 ± 11.9 43.5 ± 11.3 41.9 ± 11.3 <0.001
Men 209 (16.1) 292 (22.4) 375 (28.8) 428 (32.8) <0.001
Smoking 27 (11.9) 47 (20.7) 73 (32.2) 80 (35.2) <0.001
Body mass index †, kg/m2 28.8 ± 4.63 28.0 ± 4.41 27.8 ± 4.47 27.4 ± 4.41 <0.001
Physical activity ‡, MET-min/week 652 ± 893 561 ± 768 505 ± 762 469 ± 780 <0.001
Family history of diabetes § 76 (23.5) 85 (26.3) 80 (24.8) 82 (25.4) 0.90
Glucose-lowering medication 62 (42.8) 36 (24.8) 24 (16.6) 23 (15.9) <0.001
Lipid-lowering medication 74 (36.5) 52 (25.6) 44 (21.7) 33 (16.3) <0.001
Hypertension ¶ 152 (31.5) 127 (26.3) 105 (21.8) 98 (20.3) 0.001
Data are presented as mean ± standard deviation or n (%). * Chi-square test was used for categorical variables;
ANOVA was used for continuous variables; † Missing for 15 subjects; ‡ Missing for 296 subjects; § Missing for
2 subjects; ¶ Hypertension: SBP/DBP ≥ 130/85 or use of hypertensive medication.
Higher DII, as a continuous variable, was weakly associated with higher 2h-PG after adjusting for
sex, age, smoking status, physical activity, a family history of diabetes, hypertension, glucose lowering
medications, lipid lowering medications, and the association remained significant after inclusion
of BMI in the model. No significant associations were observed between DII and other markers of
glucose-insulin homeostasis (Table 2).
Table 2. Beta coefficients of the association between the dietary inflammatory index (DII) and
glucose-insulin homeostasis markers *.
Variables
Model 1 † Model 2 ‡
Standardized Beta p Standardized Beta p
Fasting plasma glucose, mmol/L 0.008 0.61 0.01 0.52
Postload glucose, mmol/L 0.03 0.05 0.04 0.05
Fasting insulin, µU/mL 0.01 0.42 0.02 0.17
HOMA-IR 0.02 0.38 0.02 0.15
HOMA-B 0.007 0.71 0.01 0.48
QUICKI −0.01 0.43 −0.02 0.18
* Values were loge transformed for the analysis. † Adjusted for sex, age (continuous), smoking status
(smoker, nonsmoker), physical activity (low, medium, high, or missing), a family history of diabetes (yes, no, or
missing), hypertension (yes, no), glucose lowering medications (yes, no), lipid lowering medications (yes, no);
‡ Further adjusted for variables in model 1 plus BMI category (in kg/m2; <18.5, 18.5–24.99, 25.0–29.99, ≥30.0,
or missing).
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Table 3. Adjusted mean (95% confidence interval) of glucose-insulin homeostasis markers according to quartiles of the dietary inflammatory index (DII).
Variables
Quartiles of the Dietary Inflammatory Index
Q1 (n = 743) Q2 (n = 744) Q3 (n = 744) Q4 (n = 744)








Fasting plasma glucose, mmol/L
Model 1 5.45 5.39, 5.52 5.38 5.32, 5.44 5.46 5.39, 5.52 5.46 5.39, 5.52 0.89 0.08 0.23
Model 2 5.45 5.39, 5.51 5.38 5.32, 5.44 5.46 5.39, 5.51 5.46 5.40, 5.52 0.82 0.07 0.24
Postload glucose, mmol/L
Model 1 5.67 5.51, 5.78 5.72 5.61, 5.83 5.83 5.67, 5.94 5.78 5.67, 5.89 0.15 0.53 0.28
Model 2 5.67 5.51, 5.78 5.72 5.61, 5.83 5.83 5.67, 5.94 5.78 5.67, 5.89 0.13 0.51 0.27
Fasting insulin, µU/mL
Model 1 8.15 7.84, 8.47 8.26 7.95, 8.57 8.23 7.93, 8.55 8.48 8.16, 8.81 0.16 0.33 0.53
Model 2 8.12 7.83, 8.41 8.26 7.99, 8.56 8.21 7.94, 8.50 8.52 8.22, 8.82 0.07 0.24 0.29
HOMA-IR
Model 1 1.97 1.89, 2.06 1.97 1.89, 2.05 2.00 1.91, 2.08 2.05 1.97, 2.14 0.18 0.17 0.49
Model 2 1.96 1.89, 2.04 1.98 1.90, 2.05 1.99 1.91, 2.06 2.06 1.99, 2.14 0.08 0.11 0.28
HOMA-B
Model 1 89.7 86.0, 93.5 93.4 89.5, 97.2 90.6 86.9, 94.4 92.9 89.0, 96.8 0.26 0.88 0.48
Model 2 89.4 85.8, 93.1 93.4 89.8, 97.2 90.5 86.9, 94.1 93.1 89.5, 97.0 0.17 0.92 0.34
QUICKI
Model 1 0.35 0.34, 0.35 0.35 0.34, 0.35 0.34 0.34, 0.35 0.34 0.34, 0.35 0.20 0.22 0.55
Model 2 0.35 0.34, 0.35 0.35 0.34, 0.35 0.34 0.34, 0.35 0.34 0.34, 0.35 0.09 0.16 0.33
Model 1 adjusted for sex, age (continuous), smoking status (smoker, nonsmoker), physical activity (low, medium high, or missing), a family history of diabetes (yes, no, or missing),
hypertension (yes, no), glucose lowering medications (yes, no) and lipid lowering medications (yes, no). Model 2 adjusted for variables in model 1 plus BMI (in kg/m2; <18.5,
18.5–24.99, 25.0–29.99, ≥30.0, or missing).
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Q1 Q2 Q3 Q4 ptrend
OR 95% CI OR 95% CI OR 95% CI
Glucose tolerance abnormality * (n = 1007)
Model 1 1.00 0.94 0.74, 1.19 1.11 0.87, 1.41 1.15 0.90, 1.47 0.14
Model 2 1.00 0.94 0.74, 1.19 1.10 0.87, 1.40 1.15 0.90, 1.48 0.14
Impaired fasting glucose † (n = 590)
Model 1 1.00 0.96 0.74, 1.25 1.11 0.85, 1.44 1.09 0.83, 1.44 0.36
Model 2 1.00 0.97 0.74, 1.26 1.10 0.84, 1.43 1.09 0.83, 1.44 0.37
Impaired glucose tolerance ‡ (n = 259)
Model 1 1.00 0.96 0.66, 1.39 0.99 0.68, 1.46 1.24 0.85, 1.81 0.25
Model 2 1.00 0.96 0.66, 1.40 0.98 0.67, 1.45 1.24 0.84, 1.81 0.27
Type 2 diabetes § (n = 286)
Model 1 1.00 0.96 0.67, 1.38 1.06 0.73, 1.54 0.99 0.66, 1.47 0.93
Model 2 1.00 0.96 0.67, 1.38 1.05 0.72, 1.53 0.98 0.66, 1.47 0.94
Insulin resistance || (n = 1923)
Model 1 ¶ 1.00 1.01 0.81, 1.26 0.97 0.77, 1.22 1.11 0.87, 1.40 0.47
Model 2 1.00 1.05 0.83, 1.32 0.98 0.77, 1.25 1.18 0.91, 1.51 0.29
Model 1 adjusted for age (continuous), smoking status (smoker, nonsmoker), physical activity (low, medium,
high, or missing), a family history of diabetes (yes, no), hypertension (yes, no), lipid lowering medications
(yes, no). Model 2 adjusted for variables in model 1 plus BMI (<18.5, 18.5–24.99, 25.0–29.99, ≥30.0 kg/m2,
or missing). * Including impaired fasting glucose, impaired glucose tolerance, and type 2 diabetes; † Impaired
fasting glucose was defined as fasting glucose 100–125 mg/dL; ‡ Impaired glucose tolerance was defined as 2-h
postload glucose 140–199 mg/dL; § Diabetes Mellitus was defined as fasting glucose ≥126 mg/dL or 2-h glucose
≥200 mg/dL and/or use of anti-diabetic medication; || Insulin resistance was defined as HOMA-IR ≥ 1.86 in
women and ≥1.34 in men; ¶ adjusted for glucose lowering medication.
Adjusted geometric means of glucose-insulin homeostasis markers within the quartiles of the DII
are presented in Table 3. There was no significant linear trend across quartiles of DII for adjusted means
of glucose-insulin homeostasis markers. However, participants in the highest quartile of DII score
tended to have higher FPG compared to those in the second quartile of DII score (5.46 vs. 5.38 mmol/L
for model 2, p = 0.07). After adjusting for all potential covariates (model 2) mean fasting insulin and
HOMA-IR tended to be higher among those in the highest quartile of DII score than among those
in the lowest quartile (8.52 vs. 8.12 µU/mL for fasting insulin p = 0.07; 2.06 vs. 1.96 for HOMA-IR,
p = 0.08).
About 34% of the participants had a glucose tolerance abnormality, and 64% showed IR.
Odds ratios for glucose intolerance outcomes based on the quartiles of DII are presented in Table 4.
There were no significant associations between the DII and any individual glucose tolerance
abnormalities. In addition, the risk of IR was not significantly different across quartiles of DII.
4. Discussion
In this study, the inflammatory properties of diets defined by DII in relation to glucose-insulin
homeostasis markers and risk of glucose tolerance abnormalities were investigated in a cohort of
Iranian adults. Higher DII was significantly associated with higher 2h-PG after adjustment for all
covariates. No significant positive linear trend was observed between the DII score and geometric
mean values of glucose-insulin homeostasis markers. No significant association was observed between
DII and odds of glucose tolerance abnormalities and IR.
The DII score was developed to assess the overall inflammatory quality of diet by summing
the individual inflammatory effects of different food parameters that have been published in the
literature [11]. Three cross-sectional studies conducted in US and European populations investigated
DII in relation to FBS, insulin, and HOMA-IR [21–23]. In a Dutch cohort study, each 1-SD increase in
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DII was associated with 0.9% higher FBS and 2.3% higher 2h-PG though these associations become
non-significant after inclusion of BMI to the model [21]. In a study conducted in Luxembourg
no association was observed between DII and FPG [23]. The risk of hyperglycemia defined as
FPG ≥100 mg/dL or use of glucose lowering medication was increased gradually from quartile
1 to quartile 4 of DII, and the increased risk of individuals in quartile 4 of DII was significant, compared
to those in quartile 1 after adjustment for age and BMI in police officer of US [22]. In contrast, in the
Luxemburg population study DII was not significantly associated with the risk of hyperglycemia [23].
To best of our knowledge, the associations between DII and glucose tolerance abnormalities including
IFG, IGT, T2DM, and IR have not been previously examined.
Findings of our study suggest that the DII is not associated with fasting insulin secretion, β-cell
function, and sensitivity to insulin. Therefore, the slightly positive association between the DII score
and 2h-PG may imply the role of DII in regulation of postprandial glucose through non-hepatic
mechanisms. In addition, the observation of significant association between DII and 2h-PG may be
through the effects on postprandial insulin, which has not been measured in this study. To confirm
the latter mechanism, investigating the associations between DII and postprandial markers of insulin
are required in future studies. However, the magnitude of the association between the DII and 2h-PG
was not sufficient enough to affect the risk of IGT in this study. The Dutch cohort study reported a
3.5% increase in HOMA-IR per 1-SD increase in DII in a crude model and after adjusting for age, sex,
physical activity, smoking, family history of diabetes, lipid and glucose medication, an association
that became non-significant by adding BMI to the model [21]. However, in the Luxembourg study
population no significant association was found between DII, insulin and HOMA-IR [23].
Standardizing the intake of each food parameter based on world mean and SD render the DII
scores comparable across any population. Ideally, 45 food parameters are suggested for use to calculate
the DII score [11]. However, the number of food parameters varies widely between studies, which
complicate comparability of the dietary inflammatory properties of diet estimated using different
dietary assessment instruments in different populations. Variation in DII across populations and
differences in the number and type of food parameter used to calculate DII might result in inconsistent
findings. The majority participants in our study population had anti-inflammatory diets, and the
mean score of DII in our study was −1.13 ± 1.92, which was lower than those were reported in US
populations [13,22]. Differences in DII scores in our study participants might not be large enough to
allow for detecting associations with the risk of glucose intolerance abnormalities. Further studies are
needed to examine whether DII scores are associated with glucose-insulin homeostasis and risk of
glucose tolerance abnormalities.
Objectively identified cases of diabetes, using Iranian cutoff values to identify insulin resistance,
using validated questionnaires of assessing dietary intakes and physical activity in our study
population, examining the association between DII with HOMA-B, a marker of β-cell function
in addition to markers of glucose metabolism and insulin action are some strengths of our study.
However, its cross-sectional design is the main limitation. In addition, despite using a validated FFQ,
self-reporting of diet is subject to bias and misreporting. Lastly, our participants are not a representative
sample of Iranian populations, and present findings cannot be generalized to all Iranian populations.
5. Conclusions
In conclusion, among glucose-insulin homeostasis markers, DII had a positive weak association
only with 2h-PG. DII was not significantly associated with risk of glucose tolerance abnormalities and
IR. Our findings could not show the associations of inflammation induced by diet with the risk of
glucose intolerance disorders.
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